S&P 500   4,249.15 (-0.57%)
DOW   33,381.78 (-0.71%)
QQQ   351.65 (-0.72%)
AAPL   169.48 (-1.44%)
MSFT   309.85 (-0.73%)
META   287.53 (-3.82%)
GOOGL   128.80 (+0.18%)
AMZN   125.01 (-0.77%)
TSLA   235.63 (-3.48%)
NVDA   417.69 (-0.34%)
NIO   8.36 (-0.59%)
BABA   85.60 (-0.36%)
AMD   97.03 (+1.12%)
T   14.84 (-1.20%)
F   12.28 (-1.21%)
MU   67.02 (-1.35%)
CGC   0.89 (-3.25%)
GE   110.24 (+0.28%)
DIS   79.45 (-0.75%)
AMC   7.64 (-3.41%)
PFE   32.06 (-1.05%)
PYPL   56.77 (-3.67%)
NFLX   376.36 (-0.76%)
S&P 500   4,249.15 (-0.57%)
DOW   33,381.78 (-0.71%)
QQQ   351.65 (-0.72%)
AAPL   169.48 (-1.44%)
MSFT   309.85 (-0.73%)
META   287.53 (-3.82%)
GOOGL   128.80 (+0.18%)
AMZN   125.01 (-0.77%)
TSLA   235.63 (-3.48%)
NVDA   417.69 (-0.34%)
NIO   8.36 (-0.59%)
BABA   85.60 (-0.36%)
AMD   97.03 (+1.12%)
T   14.84 (-1.20%)
F   12.28 (-1.21%)
MU   67.02 (-1.35%)
CGC   0.89 (-3.25%)
GE   110.24 (+0.28%)
DIS   79.45 (-0.75%)
AMC   7.64 (-3.41%)
PFE   32.06 (-1.05%)
PYPL   56.77 (-3.67%)
NFLX   376.36 (-0.76%)
S&P 500   4,249.15 (-0.57%)
DOW   33,381.78 (-0.71%)
QQQ   351.65 (-0.72%)
AAPL   169.48 (-1.44%)
MSFT   309.85 (-0.73%)
META   287.53 (-3.82%)
GOOGL   128.80 (+0.18%)
AMZN   125.01 (-0.77%)
TSLA   235.63 (-3.48%)
NVDA   417.69 (-0.34%)
NIO   8.36 (-0.59%)
BABA   85.60 (-0.36%)
AMD   97.03 (+1.12%)
T   14.84 (-1.20%)
F   12.28 (-1.21%)
MU   67.02 (-1.35%)
CGC   0.89 (-3.25%)
GE   110.24 (+0.28%)
DIS   79.45 (-0.75%)
AMC   7.64 (-3.41%)
PFE   32.06 (-1.05%)
PYPL   56.77 (-3.67%)
NFLX   376.36 (-0.76%)
S&P 500   4,249.15 (-0.57%)
DOW   33,381.78 (-0.71%)
QQQ   351.65 (-0.72%)
AAPL   169.48 (-1.44%)
MSFT   309.85 (-0.73%)
META   287.53 (-3.82%)
GOOGL   128.80 (+0.18%)
AMZN   125.01 (-0.77%)
TSLA   235.63 (-3.48%)
NVDA   417.69 (-0.34%)
NIO   8.36 (-0.59%)
BABA   85.60 (-0.36%)
AMD   97.03 (+1.12%)
T   14.84 (-1.20%)
F   12.28 (-1.21%)
MU   67.02 (-1.35%)
CGC   0.89 (-3.25%)
GE   110.24 (+0.28%)
DIS   79.45 (-0.75%)
AMC   7.64 (-3.41%)
PFE   32.06 (-1.05%)
PYPL   56.77 (-3.67%)
NFLX   376.36 (-0.76%)
NASDAQ:PMVP

PMV Pharmaceuticals (PMVP) Stock Forecast, Price & News

$6.14
+0.11 (+1.82%)
(As of 02:03 PM ET)
Compare
Today's Range
$5.91
▼
$6.28
50-Day Range
$6.03
▼
$8.93
52-Week Range
$3.84
▼
$13.02
Volume
125,939 shs
Average Volume
486,544 shs
Market Capitalization
$297.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

PMV Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
262.4% Upside
$22.00 Price Target
Short Interest
Bearish
18.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.79mentions of PMV Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$27,168 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.67) to ($1.92) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.49 out of 5 stars

Medical Sector

923rd out of 963 stocks

Pharmaceutical Preparations Industry

432nd out of 451 stocks

See Top Rated MarketRank™ Stocks Here

PMVP stock logo

About PMV Pharmaceuticals (NASDAQ:PMVP) Stock

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing Wild-type p53 or other p53 mutations, including R273H, R273C, R175H, G245S, R248Q, and R282W, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.

PMVP Price History

PMVP Stock News Headlines

September 20, 2023 | finance.yahoo.com
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
August 30, 2023 | finance.yahoo.com
Wall Street Analysts Think PMV Pharmaceuticals, Inc. (PMVP) Could Surge 182.64%: Read This Before Placing a Bet
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
August 29, 2023 | finance.yahoo.com
PMV Pharmaceuticals, Inc. (PMVP)'s Technical Outlook is Bright After Key Golden Cross
August 11, 2023 | msn.com
HC Wainwright & Co. Maintains PMV Pharmaceuticals (PMVP) Buy Recommendation
August 9, 2023 | finanznachrichten.de
PMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights
August 9, 2023 | finance.yahoo.com
PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights
June 20, 2023 | finance.yahoo.com
PMVP Jul 2023 5.000 call
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
June 10, 2023 | morningstar.com
PMV Pharmaceuticals Inc Ordinary Shares
May 17, 2023 | markets.businessinsider.com
The Latest Analyst Ratings for PMV Pharma
May 17, 2023 | msn.com
HC Wainwright & Co. Reiterates PMV Pharmaceuticals (PMVP) Buy Recommendation
May 12, 2023 | msn.com
Oppenheimer Reiterates PMV Pharmaceuticals (PMVP) Outperform Recommendation
May 11, 2023 | marketwatch.com
8-K: PMV Pharmaceuticals, Inc.
May 10, 2023 | finanznachrichten.de
PMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights
May 10, 2023 | finance.yahoo.com
PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights
March 27, 2023 | msn.com
Wall Street’s 10 most shorted stocks right now, including Silvergate and WeWork
March 20, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Its Buy Rating for PMV Pharmaceuticals (PMVP)
March 1, 2023 | benzinga.com
PMV Pharmaceuticals shares are trading lower after the company reported FY22 financial results.
March 1, 2023 | finance.yahoo.com
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March
March 1, 2023 | finance.yahoo.com
PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights
February 22, 2023 | finance.yahoo.com
Veterinary Pharmaceuticals Global Market Opportunities And Strategies To 2031
February 17, 2023 | nasdaq.com
Rtw Investments Now Owns 9.50% of PMV Pharmaceuticals (PMVP)
December 8, 2022 | finance.yahoo.com
Does PMV Pharmaceuticals, Inc. (PMVP) Have the Potential to Rally 267% as Wall Street Analysts Expect?
November 22, 2022 | finance.yahoo.com
PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
November 8, 2022 | finanznachrichten.de
PMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights
November 8, 2022 | finance.yahoo.com
PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights
See More Headlines
Receive PMVP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PMV Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PMVP Company Calendar

Last Earnings
8/09/2023
Today
9/27/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PMVP
CUSIP
N/A
CIK
1699382
Web
www.pmvpharma.com
Phone
609-642-6670
Fax
N/A
Employees
62
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.00
High Stock Price Forecast
$29.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+264.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.63)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-73,320,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-31.05%
Return on Assets
-28.20%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
16.63
Quick Ratio
16.63

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.39 per share
Price / Book
1.12

Miscellaneous

Outstanding Shares
48,460,000
Free Float
44,772,000
Market Cap
$292.21 million
Optionable
Not Optionable
Beta
0.93
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. David H. Mack Ph.D. (Age 61)
    Co-Founder, CEO, Pres & Director
    Comp: $762.02k
  • Dr. Arnold J. Levine Ph.D. (Age 83)
    Co-Founder, Director & Member of Scientific Advisory Board
    Comp: $140k
  • Mr. Winston Kung M.B.A.Mr. Winston Kung M.B.A. (Age 47)
    COO & CFO
    Comp: $591.29k
  • Dr. Leila Alland M.D. (Age 60)
    Chief Medical Officer
    Comp: $601.93k
  • Dr. Thomas E. Shenk Ph.D. (Age 76)
    Co-Founder & Member of Scientific Advisory Board
  • Mr. Robert Ticktin (Age 61)
    Gen. Counsel & Company Sec.
  • Mr. Tim Smith
    Sr. VP & Head of Corp. Devel.
  • Ms. Crystal Zuckerman
    VP of HR
  • Dr. Binh Vu Ph.D.
    Sr. VP of Drug Discovery & CMC
  • Dr. Deepika Jalota Pharm.D. (Age 46)
    Chief Devel. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PMVP Stock - Frequently Asked Questions

Should I buy or sell PMV Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PMV Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PMVP shares.
View PMVP analyst ratings or view top-rated stocks.

What is PMV Pharmaceuticals' stock price forecast for 2023?

2 analysts have issued 1 year price objectives for PMV Pharmaceuticals' stock. Their PMVP share price forecasts range from $15.00 to $29.00. On average, they expect the company's share price to reach $22.00 in the next year. This suggests a possible upside of 264.8% from the stock's current price.
View analysts price targets for PMVP or view top-rated stocks among Wall Street analysts.

How have PMVP shares performed in 2023?

PMV Pharmaceuticals' stock was trading at $8.70 at the start of the year. Since then, PMVP shares have decreased by 30.7% and is now trading at $6.03.
View the best growth stocks for 2023 here.

When is PMV Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our PMVP earnings forecast.

How were PMV Pharmaceuticals' earnings last quarter?

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) announced its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.09.

What ETFs hold PMV Pharmaceuticals' stock?

ETFs with the largest weight of PMV Pharmaceuticals (NASDAQ:PMVP) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC).IQ Chaikin U.S. Small Cap ETF (CSML).

What other stocks do shareholders of PMV Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PMV Pharmaceuticals investors own include Vical (VICL), Arista Networks (ANET), Apollo Medical (AMEH), Advanced Micro Devices (AMD), Ambarella (AMBA), Alexion Pharmaceuticals (ALXN), Akoustis Technologies (AKTS), Agios Pharmaceuticals (AGIO), Admiral Group (ADM) and Adobe (ADBE).

When did PMV Pharmaceuticals IPO?

(PMVP) raised $126 million in an initial public offering on Friday, September 25th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO.

What is PMV Pharmaceuticals' stock symbol?

PMV Pharmaceuticals trades on the NASDAQ under the ticker symbol "PMVP."

Who are PMV Pharmaceuticals' major shareholders?

PMV Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (10.22%), JPMorgan Chase & Co. (8.90%), Principal Financial Group Inc. (2.02%), Geode Capital Management LLC (1.63%), Woodline Partners LP (1.51%) and Bank of Montreal Can (1.53%). Insiders that own company stock include Arnold J Levine, Arnold J Levine, David Henry Mack, Deepika Jalota, Euclidean Capital Llc, Laszlo Kopits, Leila Alland, Ling Zang, Orbimed Advisors Llc, Paul Klauder, Ra Capital Management, LP, Richard A Heyman, Thilo Schroeder and Winston Kung.
View institutional ownership trends.

How do I buy shares of PMV Pharmaceuticals?

Shares of PMVP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PMV Pharmaceuticals' stock price today?

One share of PMVP stock can currently be purchased for approximately $6.03.

How much money does PMV Pharmaceuticals make?

PMV Pharmaceuticals (NASDAQ:PMVP) has a market capitalization of $292.21 million. The company earns $-73,320,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis.

How can I contact PMV Pharmaceuticals?

The official website for the company is www.pmvpharma.com. The company can be reached via phone at 609-642-6670 or via email at investors@pmvpharma.com.

This page (NASDAQ:PMVP) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -